Screener
Maravai LifeSciences Holdings, Inc. MRVI Debt Issuance Proceeds
Debt Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Maravai LifeSciences Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfLongTermDebt.
The source filing: Maravai LifeSciences Holdings, Inc.’s 10-K, filed March 18, 2025.
- Filed
- Mar 18, 2025
- Fiscal year
- FY2024
- Accession
- 0001823239-25-000034
| Line item | Year Ended December 31, 2024 | Year Ended December 31, 2023 | Year Ended December 31, 2022 |
|---|---|---|---|
| Net cash used in investing activities | (24,316) | (122,310) | (267,612) |
| Financing activities: | |||
| Distributions to non-controlling interests holders | (494) | (9,607) | (150,206) |
| Proceeds from borrowings of long-term debt, net of discount | 953 | — | 8,455 |
| Principal repayments of long-term debt | (234,393) | (5,440) | (13,895) |
| Financing costs paid to acquire long-term debt | (1,241) | — | — |
| Payments of finance lease liabilities | (633) | (332) | — |
| Proceeds from interest rate cap agreement | 9,287 | 6,168 | — |
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Maravai LifeSciences Holdings, Inc.'s debt issuance proceeds?
- Maravai LifeSciences Holdings, Inc. (MRVI) reported debt issuance proceeds of $238.25K in Q4 2024.
- What does debt issuance proceeds mean?
- Cash received from issuing bonds, notes, term loans, and other debt instruments in the capital markets or from bank lending.
Ask your AI about Maravai LifeSciences Holdings, Inc.'s debt issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude